Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.
Learn more about ENHERTU® (fam-trastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.
and a novel GGFG quadripeptide-based cleavable moiety. Recently, the FDA has approved trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2+ breast cancer and HER2+ locally advanced or metastatic gastric cancer. Preclinical evaluations andclinical ...
There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU. Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on ...
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are publishe...
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged ≥18 years with HER2...
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of...
Daiichi Sankyo Inc. Enhertu (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use. Prescribing Information. Basking Ridge, NJ: Daiichi Sankyo; revised April 2024. Keown A. Enhertu snags FDA approval for HER2-positive gastric cancer patients. BioSpace, January 18, 2021. Available...
AstraZeneca and Daiichi Sankyo’s Results from the primary analysis of the DESTINY-Lung02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to demonstrate strong and durable tumor r...
Trastuzumab deruxtecan is an antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer. Brand Names Enhertu Generic Name Trastuzumab deruxtecan DrugBank Accession Number DB14962 Background Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomeras...